Literature DB >> 28559260

Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.

Yunliang Zhang1, Ankita Kashikar1, C Adam Brown1, Gerald Denys2, Karen Bush3.   

Abstract

Carbapenemase-producing Enterobacteriaceae isolates (n = 110) from health care centers in central Indiana (from 2010 to 2013) were tested for susceptibility to combinations of avibactam (4 μg/ml) with ceftazidime, ceftaroline, or aztreonam. MIC50/MIC90 values were 1/2 μg/ml (ceftazidime-avibactam), 0.5/2 μg/ml (ceftaroline-avibactam), and 0.25/0.5 μg/ml (aztreonam-avibactam.) A β-lactam MIC of 8 μg/ml was reported for the three combinations against one Escherichia coli isolate with an unusual TIPY insertion following Tyr344 in penicillin-binding protein 3 (PBP 3) as the result of gene duplication.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  CRE; PBP 3; avibactam; aztreonam; carbapenem-resistant; carbapenemase; ceftaroline; ceftazidime; resistance

Mesh：

Substances：

Year:  2017        PMID： 28559260      PMCID： PMC5527577          DOI： 10.1128/AAC.00389-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United States.

Authors:  K Lolans; A M Queenan; K Bush; A Sahud; J P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

2.  In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.

Authors:  Yunliang Zhang; Xiaoyan Lin; Karen Bush
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

3.  Multiplex PCR for detection of acquired carbapenemase genes.

Authors:  Laurent Poirel; Timothy R Walsh; Vincent Cuvillier; Patrice Nordmann
Journal:  Diagn Microbiol Infect Dis       Date:  2011-03-12       Impact factor: 2.803

4.  Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.

Authors:  Richard A Alm; Michele R Johnstone; Sushmita D Lahiri
Journal:  J Antimicrob Chemother       Date:  2015-01-28       Impact factor: 5.790

5.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Authors:  Steven Marshall; Andrea M Hujer; Laura J Rojas; Krisztina M Papp-Wallace; Romney M Humphries; Brad Spellberg; Kristine M Hujer; Emma K Marshall; Susan D Rudin; Federico Perez; Brigid M Wilson; Ronald B Wasserman; Linda Chikowski; David L Paterson; Alejandro J Vila; David van Duin; Barry N Kreiswirth; Henry F Chambers; Vance G Fowler; Michael R Jacobs; Mark E Pulse; William J Weiss; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

7.  Detection systems for carbapenemase gene identification should include the SME serine carbapenemase.

Authors:  Karen Bush; Megan Pannell; John L Lock; Anne Marie Queenan; James H Jorgensen; Ryan M Lee; James S Lewis; Deidre Jarrett
Journal:  Int J Antimicrob Agents       Date:  2012-12-04       Impact factor: 5.283

8.  Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases.

Authors:  Y Yang; N Bhachech; K Bush
Journal:  J Antimicrob Chemother       Date:  1995-01       Impact factor: 5.790

9.  Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.

Authors:  Hanna E Sidjabat; David L Paterson; Jennifer M Adams-Haduch; Lindsay Ewan; Anthony W Pasculle; Carlene A Muto; Guo-Bao Tian; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

10.  Crystal structure of penicillin-binding protein 3 (PBP3) from Escherichia coli.

Authors:  Eric Sauvage; Adeline Derouaux; Claudine Fraipont; Marine Joris; Raphaël Herman; Mathieu Rocaboy; Marie Schloesser; Jacques Dumas; Frédéric Kerff; Martine Nguyen-Distèche; Paulette Charlier
Journal:  PLoS One       Date:  2014-05-29       Impact factor: 3.240
View more
  19 in total

1.  In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.

Authors:  James A Karlowsky; Krystyna M Kazmierczak; Samuel K Bouchillon; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

Review 3.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 4.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

Review 5.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

6.  In Vitro Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.

Authors:  Krystyna M Kazmierczak; Patricia A Bradford; Gregory G Stone; Boudewijn L M de Jonge; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 7.  Interplay between β-lactamases and new β-lactamase inhibitors.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Nat Rev Microbiol       Date:  2019-05       Impact factor: 60.633

8.  Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing Enterobacterales in the Antibiotic Resistance Laboratory Network, March 2019 to December 2020.

Authors:  Amelia Bhatnagar; Sandra Boyd; Sarah Sabour; Janine Bodnar; Elizabeth Nazarian; Nadine Peinovich; Christine Wagner; Bradley Craft; Paula Snippes Vagnone; Justin Simpson; Victoria N Stone; Michelle Therrien; Allen Bateman; Danielle Lower; Jennifer Y Huang; Stephanie Gumbis; David Lonsway; Joseph D Lutgring; Maria Karlsson; Allison C Brown
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 9.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

10.  Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study.

Authors:  Takafumi Sato; Akinobu Ito; Yoshino Ishioka; Shuhei Matsumoto; Masatomo Rokushima; Krystyna M Kazmierczak; Meredith Hackel; Daniel F Sahm; Yoshinori Yamano
Journal:  JAC Antimicrob Resist       Date:  2020-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.